It is little more than biomarker analysis. 20 patients in and dose cohort 6 is encouraging. The real miss here is how long have different patients been on therapy, what sort of responses, if any, have been seen. The study design is a little unusual in that there are single patients at starting doses before moving to a 3+3 design. Starting patients are allowed to progress thru dose escalations. The study has been open for so long that there MAY be patients that have had 10+ cycles of drug. Given patients are withdrawn if they progress this data is informative. The fact that they posted no response info, no cycle information, no adverse event data makes one lean to 'what are they hiding'.
KZA Price at posting:
9.2¢ Sentiment: None Disclosure: Held
